Xingzhe Li (Dillon Li), M.D.

Dillon Li, M.D., Assistant Professor, is a radiation oncologist at UT Southwestern Medical Center focused on treating lymphoma and pediatric cancers.

After graduating from Peking University Health Science Center summa cum laude, Dr. Li received his M.P.H. from the University of Cincinnati College of Medicine and his medical degree from the University of Kentucky College of Medicine. He completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center, which provides one of the most robust training programs in the world for lymphoma and pediatric radiation oncology. During his residency, his research focused on the genomic basis of radiosensitivity and advanced radiotherapy delivery technologies, and he has a keen interest and passion in furthering our precision and personalized radiation oncology program. In fact, as a radiation oncology resident, he was awarded an ASCO Young Investigator Award to this end.

Medical School

University of Kentucky College of Medicine (2017)

Internship

Santa Clara Valley Medical Center (2018), Transitional Year

Residency

Memorial Sloan Kettering Cancer Center (2022), Radiation Oncology

Featured Publications

Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.

Shaverdian N, Shepherd AF, Li X, Offin M, Lengel HB, Gelblum DY, Wu AJ, Simone CB, Rimner A, Jones DR, Chaft JE, Riaz N, Gomez DR, Int J Radiat Oncol Biol Phys 2022 Jun 113 2 335-344

Local Ablative Therapy in Oligometastatic NSCLC.

Li X, Gomez D, Iyengar P, Semin Radiat Oncol 2021 Jul 31 3 235-241

Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.

Li X, Kitpanit S, Lee A, Mah D, Sine K, Sherman EJ, Dunn LA, Michel LS, Fetten J, Zakeri K, Yu Y, Chen L, Kang JJ, Gelblum DY, McBride SM, Tsai CJ, Riaz N, Lee NY, JAMA Netw Open 2021 Jun 4 6 e2113205

Past, present and future of proton therapy for head and neck cancer.

Li X, Lee A, Cohen MA, Sherman EJ, Lee NY, Oral Oncol 2020 Nov 110 104879

A ribosome-associating factor chaperones tail-anchored membrane proteins.

Mariappan M, Li X, Stefanovic S, Sharma A, Mateja A, Keenan RJ, Hegde RS, Nature 2010 Aug 466 7310 1120-4

Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Santos PMG, Li X, Gomez DR, Cancers (Basel) 2022 Aug 14 16

A narrative review of intensity-modulated proton therapy for head and neck cance

Nader Mohamed, Xingzhe Li, Nancy Y. Lee Ther Radiol Oncol 2022

The inflammatory response from stereotactic body proton therapy versus stereotactic body radiation therapy: implications from early stage non-small cell lung cancer.

Li XD, Simone CB, Ann Transl Med 2019 Dec 7 Suppl 8 S295

Comparison of outcomes of stereotactic body radiation therapy delivered with three different technologies to the lung.

Kumar SS, Hall L, Li X, Downes L, Shearer A, Shelton BJ, Gerring S, McGarry RC, J Radiosurg SBRT 2018 5 3 209-216

Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.

Kumar S, Feddock J, Li X, Shearer AJ, Hall L, Shelton BJ, Arnold S, McGarry RC Int. J. Radiat. Oncol. Biol. Phys. 2017 Nov 99 3 652-659